title: Clinical microbiology costs for methods of active surveillance for Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae.
abstract: OBJECTIVE
  To compare direct laboratory costs of different methods for perirectal screening for carbapenemase-producing Enterobacteriaceae (CPE) colonization.
  
  
  METHODS
  Cost-benefit analysis.
  
  
  METHODS
  A university hospital and affiliated long-term acute care hospital (LTACH).
  
  
  METHODS
  Inpatients from the hospital or LTACH.
  
  
  METHODS
  Perirectal samples were collected from inpatients at risk for exposure to CPE. In 2009, we compared the accuracy of the Centers for Disease Control and Prevention (CDC)-recommended CPE screening method with similar methods incorporating a chromogenic agar (CA). We then performed a cost projection analysis using 2012 screening results for the CA method, the CDC method, and a molecular assay with wholesale pricing based on the 2009 analysis. Comparisons of turnaround and personnel time were also performed.
  
  
  RESULTS
  A total of 185 (2.7%) of 6,860 samples were confirmed as CPE positive during 2012. We previously found that the CDC protocol had a lower sensitivity than the CA method and predicted that the CDC protocol would have missed 92 of the CPE-positive screening results, whereas the modified protocol using CA would have missed 26, assuming similar prevalence and performance. Turnaround time was 3 days using the CDC and CA-modified protocols compared with 1 day for molecular testing. The estimated annual total program cost and total technologist's hours would be the following: CA-modified protocol, $37,441 and 376 hours; CDC protocol, $22,818 and 482 hours; and molecular testing, $224,596 and 343 hours.
  
  
  CONCLUSIONS
  The CDC screening protocol appeared to be the least expensive perirectal screening method. However, expense must be weighed against a lower sensitivity and extra labor needed for additional work-up of non-CPE isolates. The molecular test has the shortest turnaround time but the greatest expense.
authors.affiliation: Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia.
authors.forename: Amy J
authors.initials: AJ
authors.lastname: Mathers
authors.forename: Melinda
authors.initials: M
authors.lastname: Poulter
authors.forename: Dawn
authors.initials: D
authors.lastname: Dirks
authors.forename: Joanne
authors.initials: J
authors.lastname: Carroll
authors.forename: Costi D
authors.initials: CD
authors.lastname: Sifri
authors.forename: Kevin C
authors.initials: KC
authors.lastname: Hazen
mesh_terms: D001426:Bacterial Proteins / Q000096:biosynthesis* / Q000302:isolation & purification; D019411:Clinical Laboratory Techniques / Q000191:economics* / Q000379:methods; D003362:Cost-Benefit Analysis; D006785:Hospitals, University; D006801:Humans; D007711:Klebsiella pneumoniae / Q000201:enzymology / Q000302:isolation & purification*; D012680:Sensitivity and Specificity; D014768:Virginia; D001618:beta-Lactamases / Q000096:biosynthesis* / Q000302:isolation & purification
chemical_list: D001426:Bacterial Proteins; D001618:beta-Lactamases; C063912:carbapenemase